CoChat

Early Metformin in Gestational Diabetes: A Randomized Clinical Trial

Open access
Dunne, Fidelma, Newman, Christine, Alvarez-Iglesias, Alberto, Ferguson, John, Smyth, Andrew, Browne, Marie, O’Shea, Paula, Devane, Declan, Gillespie, Paddy, Bogdanet, Delia, Kgosidialwa, Oratile, Egan, Aoife, Finn, Yvonne, Gaffney, Geraldine, Khattak, Aftab, O’Keeffe, Derek, Liew, Aaron, O’Donnell, Martin · 2023 · JAMA
Cited by 90

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Importance: Gestational diabetes is a common complication of pregnancy and the optimal management is uncertain. Objective: To test whether early initiation of metformin reduces insulin initiation or improves fasting hyperglycemia at gestation weeks 32 or 38. Design, Setting, and Participants: Double-blind, placebo-controlled trial conducted in 2 centers in Ireland (one tertiary hospital and one smaller regional hospital). Participants were enrolled from June 2017 through September 2022 and followed up until 12 weeks’ postpartum. Participants comprised 510 individuals (535 pregnancies) diagnosed with gestational diabetes based on World Health Organization 2013 criteria. Interventions: Randomized 1:1 to either placebo or metformin (maximum dose, 2500 mg) in addition to usual care. Main Outcomes And Measures: The primary outcome was a composite of insulin initiation or a fasting glucose level of 5.1 mmol/L or greater at gestation weeks 32 or 38. Results: Among 510 participants (mean age, 34.3 years), 535 pregnancies were randomized. The primary composite outcome was not significantly different between groups and occurred in 150 pregnancies (56.8%) in the metformin group and 167 pregnancies (63.7%) in the placebo group (between-group difference, −6.9% [95% CI, −15.1% to 1.4%]; relative risk, 0.89 [95% CI, 0.78-1.02]; P = .13). Of 6 prespecified secondary maternal outcomes, 3 favored the metformin group, including time to insulin initiation, self-reported capillary glycemic control, and gestational weight gain. Secondary neonatal outcomes differed by group, with smaller neonates (lower mean birth weights, a lower proportion weighing >4 kg, a lower proportion in the >90% percentile, and smaller crown-heel length) in the metformin group without differences in neonatal intensive care needs, respiratory distress requiring respiratory support, jaundice requiring phototherapy, major congenital anomalies, neonatal hypoglycemia, or proportion with 5-minute Apgar scores less than 7. Conclusion and relevance: Early treatment with metformin was not superior to placebo for the composite primary outcome. Prespecified secondary outcome data support further investigation of metformin in larger clinical trials. Trial Registration: ClinicalTrials.gov Identifier: NCT02980276; EudraCT: 2016-001644-19

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2023.19869

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 90

Metadata

Authors
Dunne, F., Newman, C., Alvarez-Iglesias, A., Ferguson, J., Smyth, A., Browne, M., O’Shea, P., Devane, D., Gillespie, P., Bogdanet, D., Kgosidialwa, O., Egan, A., Finn, Y., Gaffney, G., Khattak, A., O’Keeffe, D., Liew, A., & O’Donnell, M.
Venue
JAMA
Published
2023-10-24
Volume
330
Issue
16
Pages
1547
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W4387296420
Cited by
90
References
17
FWCI
24.63
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early Metformin in Gestational Diabetes: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2023.19869
The paper
Dunne, F., Newman, C., Alvarez-Iglesias, A., Ferguson, J., Smyth, A., Browne, M., O’Shea, P., Devane, D., Gillespie, P., Bogdanet, D., Kgosidialwa, O., Egan, A., Finn, Y., Gaffney, G., Khattak, A., O’Keeffe, D., Liew, A., & O’Donnell, M. (2023). Early Metformin in Gestational Diabetes: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2023.19869

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.